Glycorex Transplantation AB (publ) financials
Glycorex Transplantation AB (publ)
549300BFHBYZ3X96EP25 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Other income | SEK 739.0K | SEK 1.3M |
| Employee benefits expense | SEK 18.9M | SEK 23.2M |
| Raw materials & consumables used | SEK 5.8M | SEK 5.2M |
| Operating profit (EBIT) | -SEK 10.4M | -SEK 30.3M |
| Finance costs | SEK 714.0K | SEK 386.0K |
| Profit before tax | -SEK 11.0M | -SEK 30.4M |
| Income tax expense | -SEK 61.0K | SEK 0 |
| Profit for the year | -SEK 10.9M | -SEK 30.4M |
| — attributable to owners | -SEK 10.9M | -SEK 30.4M |
| Total comprehensive income | -SEK 10.9M | -SEK 30.3M |
| Per share | ||
| Basic EPS | SEK -0.15 | SEK -0.41 |
| Diluted EPS | SEK -0.15 | SEK -0.41 |
| Free cash flow / share | SEK 0.00 | SEK -0.17 |
| Cash flow statement | ||
| Net cash from operating activities | SEK 101.0K | -SEK 9.5M |
| Income taxes paid | SEK 0 | SEK 0 |
| Net cash from investing activities | SEK 0 | -SEK 3.6M |
| Purchase of PP&E (capex) | SEK 0 | SEK 3.1M |
| Purchase of intangibles | SEK 0 | SEK 487.0K |
| Net cash from financing activities | -SEK 7.1M | -SEK 6.6M |
| Repayments of borrowings | SEK 654.0K | SEK 376.0K |
| Lease liability payments | SEK 6.4M | SEK 6.3M |
| Net change in cash | -SEK 7.0M | -SEK 19.6M |
| Balance sheet | ||
| Total assets | SEK 50.3M | SEK 65.8M |
| Non-current assets | SEK 31.8M | SEK 39.7M |
| Right-of-use assets | SEK 7.8M | SEK 11.6M |
| Current assets | SEK 18.5M | SEK 26.1M |
| Trade & other receivables | SEK 4.3M | SEK 3.1M |
| Cash & equivalents | SEK 5.8M | SEK 12.9M |
| Total equity | SEK 33.1M | SEK 44.0M |
| — attributable to owners | SEK 33.1M | SEK 44.0M |
| Non-current liabilities | SEK 3.0M | SEK 7.3M |
| Long-term borrowings | SEK 0 | SEK 310.0K |
| Lease liabilities (non-current) | SEK 2.9M | SEK 6.8M |
| Current liabilities | SEK 14.2M | SEK 14.5M |
| Current portion of long-term borrowings | SEK 279.0K | SEK 622.0K |
| Lease liabilities (current) | SEK 3.8M | SEK 3.8M |
| Deferred tax liabilities | SEK 116.0K | SEK 177.0K |
| Derived metrics | ||
| Free cash flow | SEK 101.0K | -SEK 12.5M |
| Return on equity | -33.0% | -68.9% |
| Cash conversion ratio | -0.01× | 0.31× |
| Capex coverage | — | -3.09× |
| Other reported items | ||
| Accruals Classified As Current | SEK 5.2M | SEK 5.7M |
| Additional Paidin Capital | SEK 119.8M | SEK 119.8M |
| Adjustments For Decrease Increase In Inventories | SEK 1.6M | -SEK 1.5M |
| Adjustments For Decrease Increase In Trade and Other Receivables | SEK 156.0K | SEK 2.4M |
| Adjustments For Increase Decrease In Trade and Other Payables | -SEK 130.0K | -SEK 1.5M |
| Adjustments To Reconcile Profit Loss Other Than Changes In Working Capital | SEK 9.5M | SEK 21.5M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 1.5M | -SEK 8.9M |
| Changes In Inventories of Finished Goods and Work In Progress | SEK 1.1M | -SEK 1.6M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 10.9M | -SEK 30.3M |
| Current Investments | SEK 988.0K | SEK 972.0K |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 1.1M | SEK 1.0M |
| Current Raw Materials and Current Production Supplies | SEK 2.2M | SEK 2.6M |
| Current Tax Assets Current | SEK 459.0K | SEK 459.0K |
| Depreciation Expense | SEK 5.9M | SEK 5.5M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -SEK 127.0K | -SEK 99.0K |
| Equity and Liabilities | SEK 50.3M | SEK 65.8M |
| Finance Income | SEK 154.0K | SEK 297.0K |
| Finished Goods | SEK 2.6M | SEK 3.7M |
| Increase Decrease Through Transactions With Owners | SEK 0 | SEK 0 |
| Intangible Assets Under Development | SEK 19.2M | SEK 22.6M |
| Issued Capital | SEK 3.7M | SEK 3.7M |
| Machinery | SEK 4.8M | SEK 5.5M |
| Number of Shares Issued | 73.9M | 73.9M |
| Office Equipment | SEK 11.0K | SEK 22.0K |
| Other Comprehensive Income | SEK 16.0K | SEK 40.0K |
| Other Comprehensive Income Net of Tax Financial Assets Measured At Fair Value Through Other Comprehensive Income | SEK 16.0K | SEK 40.0K |
| Other Current Liabilities | SEK 3.6M | SEK 2.9M |
| Other Current Receivables | SEK 1.2M | SEK 1.3M |
| Other Expense By Nature | SEK 744.0K | SEK 178.0K |
| Other Work Performed By Entity and Capitalised | SEK 0 | SEK 487.0K |
| Reserve of Gains and Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income | -SEK 13.0K | -SEK 29.0K |
| Retained Earnings Excluding Profit Loss For Reporting Period | -SEK 79.4M | -SEK 49.0M |
| Retained Earnings Profit Loss For Reporting Period | -SEK 10.9M | -SEK 30.4M |
| Revenue and Operating Income | SEK 34.8M | SEK 33.4M |
| Revenue From Sale of Goods | SEK 35.2M | SEK 30.0M |
| Trade and Other Current Payables To Trade Suppliers | SEK 1.3M | SEK 1.5M |
| Weighted Average Shares | 73.9M | 73.9M |
Every line item above is a fact tagged in Glycorex Transplantation AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.